KR102297505B1 - Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법 - Google Patents

Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법 Download PDF

Info

Publication number
KR102297505B1
KR102297505B1 KR1020160027077A KR20160027077A KR102297505B1 KR 102297505 B1 KR102297505 B1 KR 102297505B1 KR 1020160027077 A KR1020160027077 A KR 1020160027077A KR 20160027077 A KR20160027077 A KR 20160027077A KR 102297505 B1 KR102297505 B1 KR 102297505B1
Authority
KR
South Korea
Prior art keywords
aimp2
hsp70
cancer
binding
test substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020160027077A
Other languages
English (en)
Korean (ko)
Other versions
KR20170104263A (ko
Inventor
김성훈
김대규
임세미
Original Assignee
재단법인 의약바이오컨버젼스연구단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 의약바이오컨버젼스연구단 filed Critical 재단법인 의약바이오컨버젼스연구단
Priority to KR1020160027077A priority Critical patent/KR102297505B1/ko
Priority to CN201780027761.8A priority patent/CN109073638B/zh
Priority to JP2018548001A priority patent/JP6914269B2/ja
Priority to PCT/KR2017/002442 priority patent/WO2017155277A1/ko
Priority to EP17763538.0A priority patent/EP3418739B1/en
Publication of KR20170104263A publication Critical patent/KR20170104263A/ko
Priority to US16/125,113 priority patent/US11442057B2/en
Application granted granted Critical
Publication of KR102297505B1 publication Critical patent/KR102297505B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/574—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020160027077A 2016-03-07 2016-03-07 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법 Active KR102297505B1 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020160027077A KR102297505B1 (ko) 2016-03-07 2016-03-07 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법
CN201780027761.8A CN109073638B (zh) 2016-03-07 2017-03-07 抑制aimp2-dx2和hsp70结合的抗癌剂的筛选方法
JP2018548001A JP6914269B2 (ja) 2016-03-07 2017-03-07 Ａｉｍｐ２−ｄｘ２とｈｓｐ７０との結合を阻害する抗がん剤スクリーニング方法
PCT/KR2017/002442 WO2017155277A1 (ko) 2016-03-07 2017-03-07 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법
EP17763538.0A EP3418739B1 (en) 2016-03-07 2017-03-07 Method for screening anticancer agent inhibiting binding of aimp2-dx2 and hsp70
US16/125,113 US11442057B2 (en) 2016-03-07 2018-09-07 Method for screening anticancer agent inhibiting binding of AIMP2-DX2 and HSP70

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160027077A KR102297505B1 (ko) 2016-03-07 2016-03-07 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법

Publications (2)

Publication Number Publication Date
KR20170104263A KR20170104263A (ko) 2017-09-15
KR102297505B1 true KR102297505B1 (ko) 2021-09-01

Family

ID=59790548

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160027077A Active KR102297505B1 (ko) 2016-03-07 2016-03-07 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법

Country Status (6)

Country Link
US (1) US11442057B2 (enExample)
EP (1) EP3418739B1 (enExample)
JP (1) JP6914269B2 (enExample)
KR (1) KR102297505B1 (enExample)
CN (1) CN109073638B (enExample)
WO (1) WO2017155277A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101831435B1 (ko) * 2016-03-10 2018-02-22 재단법인 의약바이오컨버젼스연구단 Aimp2-dx2 단백질에 특이적으로 결합하는 항체
US11758948B2 (en) 2018-01-29 2023-09-19 Altria Client Services Llc Lighting unit for aerosol-generating systems
RU2764430C1 (ru) 2018-01-29 2022-01-17 Филип Моррис Продактс С.А. Блок подсветки для систем, генерирующих аэрозоль
KR102308134B1 (ko) 2018-04-26 2021-10-01 재단법인 의약바이오컨버젼스연구단 mTOR 저해제로서의 신규 화합물 및 이의 용도
CN117769431A (zh) * 2021-03-30 2024-03-26 德克萨斯大学体系董事会 瓜氨酸化蛋白作为用于癌症的生物标志物和疗法靶
CN115786504B (zh) * 2022-08-31 2023-09-19 中国人民解放军总医院京南医疗区 Hspa4抑制剂在治疗黑素瘤中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117572A1 (en) 2004-11-24 2011-05-19 Neomics Co., Ltd. Antibody Specific to the AIMP2-DX2
KR101577315B1 (ko) 2013-03-14 2015-12-15 부산대학교 산학협력단 AIMP2-DX2와 p14/ARF의 상호작용을 이용한 암 치료제의 스크리닝 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US7459529B2 (en) 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
KR20060057992A (ko) * 2004-11-24 2006-05-29 재단법인서울대학교산학협력재단 ｐ38-ＤＸ2 및 이의 용도
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20080280297A1 (en) * 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
KR20070113926A (ko) * 2006-05-26 2007-11-29 재단법인서울대학교산학협력재단 암의 진단과 치료를 위한 ａｉｍｐ2ｄｘ2의 용도
US8754094B2 (en) * 2007-08-15 2014-06-17 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
KR101067816B1 (ko) * 2007-11-09 2011-09-27 (주)네오믹스 Ａｉｍｐ2-ｄｘ2의 억제제를 유효성분으로 포함하는 염증성질환 예방 및 치료용 조성물
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
CN102985103A (zh) * 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
WO2013006076A1 (en) * 2011-07-04 2013-01-10 New York University The use of intranasally administered hsp70 protein to treat neurodegenerative diseases
KR20130016041A (ko) * 2011-08-04 2013-02-14 재단법인 의약바이오컨버젼스연구단 신규한 아닐린 유도체 및 이의 용도
KR101500804B1 (ko) * 2012-04-20 2015-03-11 단국대학교 산학협력단 Ａｉｍｐ２ 유전자의 스플라이싱 변이체 특이적인 트랜스-스플라이싱 활성을 갖는 핵산 분자 및 이를 이용한 폐암 치료용 약학 조성물 및 폐암 진단용 조성물
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
KR101464360B1 (ko) * 2012-11-09 2014-11-21 주식회사 대웅 리보자임과 shRNA를 함유하는 아데노바이러스 및 이를 포함하는 암 치료용 조성물
KR101762433B1 (ko) * 2013-06-05 2017-07-28 재단법인 의약바이오컨버젼스연구단 신규한 말레인산 유도체 및 이의 제조방법 및 이를 포함하는 항암용 조성물
KR101514320B1 (ko) * 2013-06-14 2015-04-22 재단법인 의약바이오컨버젼스연구단 신규한 암 예방 또는 치료용 약학적 조성물
KR101621963B1 (ko) * 2014-03-06 2016-05-17 한국과학기술원 Aimp2의 엑손2 결손체 돌연변이 검출용 분자신호기 및 이를 이용한 aimp2 돌연변이의 검출방법
EP3162803B1 (en) * 2014-06-30 2019-09-11 Pusan National University Industry-University Cooperation Foundation New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117572A1 (en) 2004-11-24 2011-05-19 Neomics Co., Ltd. Antibody Specific to the AIMP2-DX2
KR101577315B1 (ko) 2013-03-14 2015-12-15 부산대학교 산학협력단 AIMP2-DX2와 p14/ARF의 상호작용을 이용한 암 치료제의 스크리닝 방법

Also Published As

Publication number Publication date
US11442057B2 (en) 2022-09-13
CN109073638B (zh) 2022-04-26
EP3418739B1 (en) 2021-05-12
CN109073638A (zh) 2018-12-21
KR20170104263A (ko) 2017-09-15
WO2017155277A1 (ko) 2017-09-14
US20190033295A1 (en) 2019-01-31
WO2017155277A8 (ko) 2018-11-08
JP6914269B2 (ja) 2021-08-04
EP3418739A4 (en) 2019-03-06
JP2019512693A (ja) 2019-05-16
EP3418739A1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
KR102297505B1 (ko) Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법
Li et al. Ubiquitination and deubiquitination emerge as players in idiopathic pulmonary fibrosis pathogenesis and treatment
Chen et al. Targeting USP9x/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid
Amir et al. MSF-A interacts with hypoxia-inducible factor-1α and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis
Zhou et al. Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC
US9597369B2 (en) Inhibitors of atypical protein kinase C and their use in treating hedgehog pathway-dependent cancers
Kim et al. Inhibition of heat shock protein 27–mediated resistance to DNA damaging agents by a novel PKCδ-V5 heptapeptide
D'Amore et al. “Janus” efficacy of CX-5011: CK2 inhibition and methuosis induction by independent mechanisms
Borghouts et al. The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death
Panner et al. Heat shock protein 90α recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma
Zhu et al. TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells
Wang et al. PINCH-1 promotes IGF-1 receptor expression and skin cancer progression through inhibition of the GRB10-NEDD4 complex
Zhu et al. Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant‐dependent manner
EP2857392A1 (en) Small compound targeting at tacc3
KR101367832B1 (ko) 종양 억제 타겟으로서 Ｈａｄｅｓ의 용도
Wang et al. RGS-GAIP–interacting protein controls breast cancer progression
KR101771070B1 (ko) Mrs와 cdk4의 결합을 저해하는 항암제 스크리닝 방법
KR102290511B1 (ko) AIMP2-DX2와 K-Ras의 결합을 저해하는 항암제 스크리닝 방법
Ludwig et al. The tumor suppressor, p190RhoGAP, differentially initiates apoptosis and confers docetaxel sensitivity to breast cancer cells
US8304399B2 (en) Hedgehog signaling pathway proteins and uses thereof
KR100880850B1 (ko) 고형암 세포에서 사이클로필린 ａ의 발현을 억제하는물질을 포함하는 시스플라틴에 대한 내성 억제용 약제학적조성물 및 그를 이용하여 고형암의 시스플라틴에 대한내성을 억제하는 방법
JP2009502113A (ja) 乳癌を治療するための組成物および方法
US20130345145A1 (en) Atip3 and biologically active fragments thereof for use in the treatment of cancer
KR20260020417A (ko) 암 치료용 omomyc 및 kras 저해제 조합 요법
Han et al. Interaction of integrin linked kinase (ILK) and MCM7 mediating integrin α7 induced cell growth suppression

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000